Draft:Centrient Pharmaceuticals

Centrient Pharmaceuticals
Centrient Pharmaceuticals is a leading global business-to-business pharmaceutical company specializing in the production of sustainable antibiotics, next-generation statins, and anti-fungals. The company is renowned for its commitment to innovation and sustainability in pharmaceutical manufacturing.

History
Centrient Pharmaceuticals traces its roots back to 1869. Originally established as ‘Nederlandsche Gist- en Spiritusfabriek’, the company later became known as Gist Brocades and then DSM Sinochem Pharmaceuticals. In 2018, Bain Capital acquired the company and it was rebranded as Centrient Pharmaceuticals.

Headquarters and Global Network
The company is headquartered in Rijswijk, Netherlands, and operates manufacturing sites and sales offices across the globe. Key manufacturing locations include Delft in the Netherlands, Santa Perpètua de Mogoda in Spain, Toansa in India, Ramos Arizpe in Mexico, and two sites in China located in Changchun and Zibo. Sales offices are located in multiple regions including North America, Latin America, Europe, and Asia.

Products
Centrient's product portfolio includes:
 * Antibiotics: Including various penicillins and cephalosporins.
 * Statins: Used for managing cholesterol levels.
 * Anti-fungals: Such as Nystatin.

The company produces both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), ensuring a comprehensive supply of essential medicines.

Enzymatic Production Innovation
Centrient Pharmaceuticals is known for pioneering the enzymatic production of penicillins and cephalosporins. This process involves the use of enzymes to catalyze chemical reactions in the production of these antibiotics, making the process more environmentally friendly and efficient compared to traditional chemical synthesis. The enzymatic method reduces the use of harmful solvents and lowers energy consumption, aligning with the company's sustainability goals. This innovation has positioned Centrient as a leader in sustainable antibiotic production.

Vertically Integrated Manufacturer
Centrient is the only vertically integrated Western-based merchant antibiotic manufacturer. This means they produce the fermentative intermediate, the final API, and the finished dose in Western countries. As a business-to-business merchant player, Centrient supplies many major global and leading regional pharmaceutical companies with APIs and FDFs.

Purpose and Sustainability Initiatives
Centrient's purpose is to improve lives through innovative and sustainable manufacturing of medicines, saving the lives of millions of people worldwide annually. The company employs advanced wastewater treatment technologies, such as Mechanical Vapor Recompression (MVR), to enhance water recovery and reduce environmental impact. Their Toansa site in India exemplifies their commitment to environmental stewardship.

Recent Developments
In October 2023, Centrient partnered with Almirall to join its innovation hub in Barcelona. This collaboration aims to enhance Centrient’s research and development capabilities, focusing on biotechnology, strain and enzyme development, and sustainable manufacturing processes.

Leadership
The current CEO of Centrient Pharmaceuticals is Rex Clements, who took over the role in March 2020. Clements has a dual MBA in Strategy and General Management from the Wharton School of the University of Pennsylvania, and a Bachelor of Science in Chemical Engineering from the University of Stellenbosch. Before joining Centrient, he held several senior roles at Sandoz, a division of Novartis.